SOURCE: CWR & Partners

January 20, 2010 12:31 ET

SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record

SAN DIEGO, CA and ATTLEBORO, MA--(Marketwire - January 20, 2010) - CWR & Partners, LLP (CWR) announced today that it has been named the public relations agency for SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company specializing in spectrophotometry systems.

CWR's mandate and focus will be to leverage its broad base of relationships within the healthcare national and trade media to raise national and international awareness for SpectraScience and its optical biopsy systems. Veronica Welch, Principal at CWR, said, "We think optical biopsy is the next frontier for cancer screening, offering several advantages over the incumbent narrowband imaging technology, and SpectraScience has a deep IP portfolio which will position it as a leader in the space."

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT® Optical Biopsy System and LUMA® Cervical Imaging Systems. These devices are used to assess tissue quickly to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

"SpectraScience is introducing leading edge technologies to dramatically improve cancer screening treatment as well as patient outcomes and we are pleased to help promote them," said Welch. "To date, typical cancer screening consists of multiple physical biopsies and invasive procedures that cost more and are frequently inaccurate. We chose to work with SpectraScience because their technology will not only change the way cancer screening is done for patients and doctors but it will also save time, money and lives. We are honored to work for such a cause."

CWR has a ten year history of promoting companies through pro-active media relations that builds awareness, increases sales and ultimately creates strong products. CWR has successfully branded companies in several different markets including medical device, financial, consumer products, technology and various other industries. CWR clients are frequent experts seen on CNN, Fox News, ABC, etc.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

About CWR:

CWR & Partners, LLP, based in Attleboro, MA, was founded in 2001 by public relations industry veterans Kelly Cinelli and Veronica Welch. Over the past nine years, the agency has used its public relations skills to garner media placements for their clients in thousands of publications across the U.S. and abroad. The company has contacts at all national publications in every media venue. For more information please call 508-222-4802 or visit

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information